Carboplatin

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

Carboplatin Chemical Structure

Molecular Weight(MW): 371.25

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Size Price Stock Quantity  
USD 77 In stock
USD 107 In stock
USD 167 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) The BRCA1-mutated TNBC cell lines MDA-MB-436 and HCC1937 were treated with CBP (10 μM) plus GEM (100 nM) combined with or without olaparib (10 μM) for the indicated times, and then, the cell viability was determined with an MTT assay. The results show data from six independent experiments expressed as the mean ± SD. p < 0.05.

    Sci Rep, 2017, 7:42319. Carboplatin purchased from Selleck.

    Detection of apoptotic responses was found to increase in epimorphin-treated  A1847 with increasing concentrations of carboplatin compared to those of the untreated controls. Data were normalized to the controls and are represented as means ± S.D. [*p<0.05 compared with control]. Images of apoptotic cells were captured at 10X magnification, with at least 3 images per well, using an upright phase-contrast microscope (T3.15A; Fisher Scientific).

    PLoS One 2012 8, e72637. Carboplatin purchased from Selleck.

  • A. MCF10A-Ras overexpressing a vector control or the gene of interest (GeneX), or MCF7 expressing a scramble or a siRNA for the geneX were treated with DMSO or with Carboplatin for 24h. Resistant colonies were allowed to grow for 2 weeks, and are then stained with Crystal Violet. B. Quantification of the results.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Carboplatin for 48h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.
Features A DNA synthesis inhibitor.
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  M2O4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TiNVIuOjYkgJpOwG0> NF3XOnY4OiCq MVzpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 Mmq4NlYyOzdzMEW=
Tca8113/CBP  M3m2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TS[|IuOjYkgJpOwG0> MmLzO|IhcA>? MXnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NH73WmczPjF|N{GwOS=>
Tca8113/PYM  M3vBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofINk0zPeLCid88US=> MYS3NkBp M1mxb4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NYe1ZoY1OjZzM{exNFU>
SKOV3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1mxNlYxKG2pL33s MWWxMVUh\A>? MUPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSC2aX3lJIRmeGWwZHXueIx6 NFLWO|MzPjF|N{C0Ny=>
SKOV3 NYXzdY5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPxS5cxNTRizsznM41t NWPPe5pKOjRxNEivO|IhcA>? MWPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 M{PVcFI3OTJ3Mkez
SKOV3 NFnxRXlCeG:ydH;zbZMhSXO|YYm= NX24cpNuOiEQvHevcYw> NEjqfYQ1QCCq MUnpcoR2[2W|IHHwc5B1d3Orcx?= M{DnV|I3OTJ3Mkez
OSA M3XJTWNtd26xZ3XubYMhSXO|YYm= NH2wNpgzNjVxNTFOwG0> MmP3doV{fWy2czDpckBtd3encjDjc4xwdnliZn;ycYF1cW:wIHHzJINwdXCjcnXkJJRwKGWrdHjldkBDVUlzIIPpVm5CKHS{ZXH0cYVvfA>? M1zPT|I3OTFyNkKw
A549 MVnGeYN1cW:wIFHzd4F6 NFnJW|gxNzJ3L{WwJO69VQ>? M4f1PVI1KGh? M4nPXYRwf26{ZXf1cIF1\XNibXnSMVIxPSCneIDy[ZN{cW:wwrC= MmTvNlU6OTd|MUe=
H1975 Ml\iSpVkfGmxbjDBd5NigQ>? M4nKS|AwOjVxNUCg{txO MlXQNlQhcA>? NYrCPJZ1\G:5boLl[5Vt[XSnczDtbXIuOjB3IHX4dJJme3Orb39CpC=> NYnJeVUzOjV7MUezNVc>
A549 NV\6OFN{TnWldHnvckBCe3OjeR?= M2f3dFAwOjVxNUCg{txO M2jLTVI1KGh? MWX1dJJm\3WuYYTld{BucVJvMkG4JIV5eHKnc4Ppc44> NYLk[mFoOjV7MUezNVc>
H1975 NX\OV3EyTnWldHnvckBCe3OjeR?= M165cVAwOjVxNUCg{txO MVuyOEBp MlyweZBz\We3bHH0[ZMhdWmULUKxPEBmgHC{ZYPzbY9v MkGyNlU6OTd|MUe=
A549 NF;nblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vnUlI2KM7:TR?= NG\6cIozPCCq M3flNYlvcGmkaYTzJINmdGxiZ4Lve5Rp MoXENlU6OTd|MUe=
H1975 NV;1[JE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLINlUh|ryP Ml;DNlQhcA>? M1PBd4lvcGmkaYTzJINmdGxiZ4Lve5Rp NUnDfFkxOjV7MUezNVc>
MDA-MB-231 M3[xSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TMNVAuOjJyIN88[{9udA>? NWnJSGRRPzJiaB?= NFTGTIxKSzVywrC9JFg3KM7:TR?= NVv4eokzOjV6M{e2PVE>
T47D MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3JWGVYOC1{MkCg{txoN22u NVrXTXc1PzJiaB?= Mn;GTWM2OMLiPTC0PE46KM7:TR?= MkXoNlU5Ozd4OUG=
LCTCC MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT3XJBKSzVyPUOuPQKBkcL3TR?= NWjxOJVFOjV5N{OxOlc>
MCTCC NXrVWXhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H2e2lEPTB;Mj645qCKyrWP MVuyOVc4OzF4Nx?=
MegTCC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrYXlZtUUN3ME20MlHjiIoEtV2= NVTPSotGOjV5N{OxOlc>
MonoTCC NUf3SlJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3LNZhKSzVyPUWuOwKBkcL3TR?= MW[yOVc4OzF4Nx?=
MCF7 NVPtOpp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWiyNEDPxE1? M3fsTFczKGh? NXPnUW9IcW6mdXPld{Bk\WyuIHTlZZRpKG:oIFjQNe6zNWSncHzleIVlKE2FRkegZ4VtdHN? MlTONlU4PjlyMkW=
A-549  MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fTWVAvPSEQvF2= NH\wZ5MzPCCq M2PaVmROW00EoB?= NWfoWIh4cW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> MknpNlU4PTV4OUC=
A-549  MVPBdI9xfG:|aYOgRZN{[Xl? MlLWNE42KM7:TR?= MUi0PEBp MoPsSG1UV8Li MXvzbI94eyCnYYLsfUBieG:ydH;zbZMh\mWjdIXy[ZMhcW6lbIXkbY5oKGKuZXLibY5oKGGwZDDjbJJwdWG2aX6gZ49v\GWwc3H0bY9v M4X4R|I2PzV3Nkmw
A-549  MlvuSpVkfGmxbjDBd5NigQ>? M2fNT|AvPSEQvF2= MVO0PEBp NVe4SIdMTE2VT9Mg NW\WTIg5e2ixd4OgZYJmenKjboSgcYlkem:2dXL1cIUh\Gm|coXweIlwdg>? NGf3ZVkzPTd3NU[5NC=>
A-549  M1zLU2Z2[3Srb36gRZN{[Xl? MWKwMlUh|ryP NXvQS|JMPDhiaB?= Mn7OSG1UV8Li NUX1fIV3cW6qaXLpeJMhd2ZiY3XscEBucWe{YYTpc47DqA>? NHe5XIMzPTd3NU[5NC=>
RMG-1 M{S1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XGb2lEPTB;MkiuPEDDuSB|Lk[gcYcwVA>? M1TZZ|I2PzJ4OUGz
FN-RMG-1 MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHzTWM2OD12MD61JOKyKDRwMjDt[{9NEiEQvF2= NYPHS|REOjV5Mk[5NVM>
RMG-1-hFUT NEm0TVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTV6LkGgxtEhOi52IH3nM2w> NVfYVlk2OjV5Mk[5NVM>
FN-RMG-1-hFUT MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT4[G5WUUN3ME2xNVgvQCEEsTCxN{45KG2pL1y= MXeyOVczPjlzMx?=
CHP-134  NELVU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17YNlEh|ryP MlrKSG1UV8Li NXzaXHNPcW6qaXLpeJMhe2mpbnnmbYNidnRiY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCJU1uyPFMxOzdz Mk\kNlU3PTh2NkO=
IMR-32 MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHiNXoyKM7:TR?= MnWxSG1UV8Li NGjG[49qdmirYnn0d{B{cWewaX\pZ4FvfCClZXzsJIdzd3e2aDDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? MYeyOVY2QDR4Mx?=
CHP-134  M2PjSGZ2[3Srb36gRZN{[Xl? MXKxNEDPxE4EoB?= MWXEUXNQyqB? NEnoZpJqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? M2fFV|I2PjV6NE[z
IMR-32 NGSxSZRHfWO2aX;uJGF{e2G7 Mn6yNVAh|ryPwrC= MmHiSG1UV8Li M1TYRolv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBIW0t{OEOwN|cy NH\GfJIzPTZ3OES2Ny=>
A549 NEf3SVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSwMlIuPDByMDFOwG0> M4i4TVczKGh? NFnKcI5KSzVyPUGyOkDDuSB3LkCg{txO MnX0NlU3OjV{NEO=
A549/CDDP MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NISx[W8xNjJvNECwNEDPxE1? MWq3NkBp M{SwdGlEPTB;MkSwxsDDucLiNEWuO{DPxE1? M1vpVVI2PjJ3MkSz
H460  NXHmS4hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nJRlI1KGh? MnzaSG1UVw>? NUTqN|B6UUN3ME23Mlkh|ryP MXOyOVU6QTl7NR?=
H460  M1PCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXO3Mlkh|ryP MVyyOEBp MoHwSG1UVw>? NUTrbGQ{e2ixd4OgZUBz[WSrb4PlcpNqfGm8aX7nJIVn\mWldDD0c{BZNXKjeYO= NFfLPI8zPTV7OUm5OS=>
NRK-52E NETwPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXSN2Y6PzMEoHlCpC=> M4TWcmlEPTB;MUCwJOKyKDF{Lkmg{txO MmX4NlU2PjV4MEO=
RGE M2HCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHK5VZk4OsLiaNMg NX3ndJhQUUN3ME2yNkDDuSB5LkSg{txO M3O0[FI2PTZ3NkCz
NRK-52E NF[wWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;oO|LDqGkEoB?= NI[5b4JKSzhyPUG3PUDDuSB7LkWg{txO M2HEPFI2PTZ3NkCz
RGE NWfIbJNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPRU5Z4PzMEoHlCpC=> MWLJR|gxRTZ|INMxJFcvPCEQvF2= Mo[xNlU2PjV4MEO=
SK-OV-3 MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[3NkBp MYPJR|UxRTFyND64JO69VQ>? NU\DTmd2OjV3MkCxN|I>
ES-2 M2\0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvUS2g4OiCq NVzFTZhKUUN3ME2xOE43KM7:TR?= NVvQSnpkOjV3MkCxN|I>
OVCAR-8 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXS3NkBp MoPSTWM2OD17Nj6wJO69VQ>? MnnGNlU2OjBzM{K=
3AO NW[wUlV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXTZZFRPzJiaB?= NFvxfYFKSzVyPU[zMlQh|ryP M1:3NFI2PTJyMUOy
A2780 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz4O|IhcA>? M2TPbGlEPTB;MUS1Mlch|ryP M4LXTlI2PTJyMUOy
SW626 M1eyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf0foc4OiCq MmTCTWM2OD17Nz6wJO69VQ>? M4jsS|I2PTJyMUOy
OVCAR-3 NXXRR415T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPZWWVzPzJiaB?= NW\kTmZXUUN3ME2zNk43KM7:TR?= M3PrOlI2PTJyMUOy
A549 NGjVbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nkW2lEPTB;MUWxMlU3KMLzIEWzMlA3KM7:TR?= M1r5dVI2Ojd5NE[x
4T1 M3\BO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PCNGlEPTB;OESuOlIhyrFiM{CuNFUh|ryPCjFOwG0> M4rIUlI2Ojd5NE[x
BALB/3T3 Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zUWGlEPTB;MUSuN|AhyrFiNj62PEDPxE1? MlvnNlUzPzd2NkG=
B16 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTZ2LkOwJOKyKDZwOEGg{txO M{P0bVI2Ojd5NE[x
DU 145 M36ySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\hb5Z7UUN3ME2zOU4xPCEEsTCxO{42PCEQvF2= NWfqOYFXOjV{N{e0OlE>
FaDu NV7SZ|I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zB[mlEPTB;NEWuN|khyrFiMUGuOVAh|ryP MmTiNlUzPzd2NkG=
HCV-29T M{e4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTR6LkW3JOKyKDJ{LkS5JO69VQ>? M4\JVFI2Ojd5NE[x
HL-60 MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlW3TWM2OD1zMT6xNEDDuSB2LkS3JO69VQ>? NGDTOFYzPTJ5N{S2NS=>
HT-29 M3ntZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf0R4tKSzVyPUi5MlE3KMLzIEG4Mlg3KM7:TR?= M3LwR|I2Ojd5NE[x
H146 NWHocnVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW3TWM2OD12OT62xtEyOy5zIN88US=> M{HkW|I2OTJ2Mkiy
H187 MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTF{LkhCtVIvPyEQvF2= NXPpR|lnOjVzMkSyPFI>
H128 M4fVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPaTpFKSzVyPUGwOk41yrF7Lk[g{txO M1rITlI2OTJ2Mkiy
H69 Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ywUWlEPTB;N{[uPeKyOjdwODFOwG0> MWCyOVEzPDJ6Mh?=
H209 M2rOcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfCTWM2OD1{NUiuNeKyQTlwODFOwG0> Mmn0NlUyOjR{OEK=
DMS153 NEC5OlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC3O5hNUUN3ME21O{45yrF7LkKg{txO NWTXSZNTOjVzMkSyPFI>
H526 M2G5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO1UIcyUUN3ME23MlLDuTFwNzFOwG0> MVOyOVEzPDJ6Mh?=
DMS114 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\0TWM2OD16NT64xtEyOi56IN88US=> MnnHNlUyOjR{OEK=
DMS53 MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjhTWM2OD1zNE[uNuKyOzZwNDFOwG0> NVXSV5M4OjVzMkSyPFI>
HeLa M1;Sc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nTUlUuQDBizszN NF\BV45qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M2nFN|I2OTB7M{[w
MCF-7 M3ntVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvxfXpTPS16MDFOwG0> NIH2OY5qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M{PEflI2OTB7M{[w
MDA-MB-231 NHXPb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXG1MVgxKM7:TR?= NX34[GtpcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M1rydFI2OTB7M{[w
CaOV3 MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzzO|IhcA>? MnTrTWM2OD16Nj6xJO69VQ>? NHHnR|YzPTB4OEi0PS=>
OVCAR-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm0W3k4OiCq MmHYTWM2OD1zN{muOUDPxE1? NF3ze3MzPTB4OEi0PS=>
OVCAR-5 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWC3NkBp NELuO2tKSzVyPUe1Mlch|ryP M1qzXlI2ODZ6OES5
SKOV-3 M{HMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PtdlczKGh? NXnJW2NPUUN3ME21NFQh|ryP NV\3cHBmOjVyNki4OFk>
OVCAR-4 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXufVlvPzJiaB?= MnnrTWM2OD1{OUCuOkDPxE1? MXmyOVA3QDh2OR?=
OVCAR-8 Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vm[FczKGh? MWHJR|UxRTZ7MD6yJO69VQ>? NUHFeFFROjVyNki4OFk>
MA148 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHwT3EzPCCq NHLZO4FKSzVyPUizMlbjiIoEsfMAjVEvPCEQvHevcYw> MVyyOFg{OTB7MR?=
A549 NH\DOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTTTZlFOjRiaB?= M{DPRmlEPTB;N{e2MlDjiIoEsfMAjVEvQSEQvHevcYw> MXqyOFg{OTB7MR?=
MDA-MB-231 NV\WV4FTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPxNlQhcA>? MVjJR|UxRTd2OD6w5qCKyrIkgJmxMlEh|rypL33s NH;YPHkzPDh|MUC5NS=>
NCI-ADR/RES  M1z6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmyOEBp NXPmb3I4UUN3ME2xO|U{NjEkgJpCtgKBkTRwNDFOwIcwdWx? NGHZW3QzPDh|MUC5NS=>
MA148 NIrhN|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP1OFghcA>? MVzJR|UxRTJ6LkJihKnDueLCiUGuNEDPxGdxbXy= NIToRVczPDh|MUC5NS=>
A549 NX;pcWxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XMZlQ5KGh? MnTwTWM2OD1zMUiuNQKBkcLz4pEJNU4zKM7:Zz;tcC=> MoPRNlQ5OzFyOUG=
MDA-MB-231 NW\3eYwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHOOFghcA>? MVnJR|UxRTF6Mz6w5qCKyrIkgJmxMlIhKM7:Zz;tcC=> MVqyOFg{OTB7MR?=
NCI-ADR/RES  M1vuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILxTVA1QCCq MVnJR|UxRTF7Mz6w5qCKyrIkgJmxMlkh|rypL33s NWO3dG12OjR6M{GwPVE>
MA148 Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDKZpBKPzJiaB?= Mk\ITWM2OD1zMz635qCKyrIkgJmxMlIh|rypL33s MkfkNlQ5OzFyOUG=
A549 MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\td2dwPzJiaB?= NXTLboU3UUN3ME22OE4{6oDLwsJihKkyNjFizsznM41t NF2x[ogzPDh|MUC5NS=>
MDA-MB-231 NF3BWXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M32zWlczKGh? NGTQUJdKSzVyPUm5MlXjiIoEsfMAjVEvOSEQvHevcYw> NIHHPW8zPDh|MUC5NS=>
NCI-ADR/RES  NFfuS5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXq3NkBp MV;JR|UxRTN5LkVihKnDueLCiUGuO{DPxGdxbXy= NH[2OJIzPDh|MUC5NS=>
A549 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDIO|IhcA>? NIXFU4FFVVOR NXviOFRRUUN3ME2xOVIvPDB7IN88US=> M165[|I1PzJzM{Kz
NCI-H157 MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zqbVczKGh? NY[1XoxTTE2VTx?= M1P2SWlEPTB;OEmuPVc4KM7:TR?= MXqyOFczOTN{Mx?=
PC9 Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\JO|IhcA>? M4LoV2dEPTB;N{GuOuKyQS53INM1US=> MYiyOFYyQDhyOR?=
A549  MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPJd5c4OiCq MU\HR|UxRTF|NtMxN|EvPiEEtV5CpC=> NWfhc3VqOjR4MUi4NFk>
PC9 M4TlOWFxd3C2b4Ppd{BCe3OjeR?= M4TsZ|ExOCEEtV2= M4TsO|czKGh? MUfpcoR2[2W|IHHwc5B1d3Orcx?= MmXpNlQ3OTh6MEm=
A549  Mn\aRZBweHSxc3nzJGF{e2G7 MmjKNVAxKML3TR?= M3K4SFczKGh? M2T6NYlv\HWlZYOgZZBweHSxc3nz NEHYWYUzPDZzOEiwPS=>
A549 M2HHS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPaNlQhcA>? NVPEXJRoUUNzME2xMlQ4PiCwTR?= NYrRSlZDOjR|OU[0N|c>
H1299 Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:3bGUzPCCq NXPuXGdtUUNzME2wMlQ1OyCwTR?= MVKyOFM6PjR|Nx?=
HCC15 NETxTXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWiyOEBp MWjJR|ExRTBwM{S2JI5O NF;meVczPDN7NkSzOy=>
H157 M2XV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYqyOEBp MYLJR|ExRTBwOEGgcm0> NH\KWWszPDN7NkSzOy=>
A2780 MkX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnySW1KSzVyPUG0MlDjiIoEsfMAjVEvPCEQvF2= M1XTXVI1OjB7Nkmz
A2780cisR NYDzRpgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[1V5JKSzVyPUS4MlnjiIoEsfMAjVMvQSEQvF2= NHnXN2wzPDJyOU[5Ny=>
A2780ZD0473R NF:zR|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHLTWM2OD14ND625qCKyrIkgJmzMlIh|ryP M{X6[|I1OjB7Nkmz
SKOV-3 NGTLU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rCTmlEPTB;NEOuOQKBkcLz4pEJN{46KM7:TR?= M4TnV|I1OjB7Nkmz

... Click to View More Cell Line Experimental Data

In vivo In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Formulation: Carboplatin is dissolved in 43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water.
  • Dosages: ≤60 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
water
For best results, use promptly after mixing.
14mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage powder
Synonyms JM-8, CBDCA, NSC 241240

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT02124902 Recruiting Triple Negative Breast Neoplasms Washington University School of Medicine July 7, 2014 Phase 2
NCT02941523 Not yet recruiting Cancer Noxopharm Limited March 6, 2017 Phase 1|Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03032614 Not yet recruiting Breast Cancer Stage IV|Ovarian Cancer|BRCA1 Mutation|BRCA2 Mutation The University of Texas Health Science Center at San Antonio March 31, 2017 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID